Cargando…

New-age vaccine adjuvants, their development, and future perspective

In the present scenario, immunization is of utmost importance as it keeps us safe and protects us from infectious agents. Despite the great success in the field of vaccinology, there is a need to not only develop safe and ideal vaccines to fight deadly infections but also improve the quality of exis...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Shailendra Kumar, Mahajan, Pooja, Singh, Nikhlesh K., Gupta, Ankit, Aggarwal, Rupesh, Rappuoli, Rino, Johri, Atul Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998920/
https://www.ncbi.nlm.nih.gov/pubmed/36911719
http://dx.doi.org/10.3389/fimmu.2023.1043109
_version_ 1784903556988403712
author Verma, Shailendra Kumar
Mahajan, Pooja
Singh, Nikhlesh K.
Gupta, Ankit
Aggarwal, Rupesh
Rappuoli, Rino
Johri, Atul Kumar
author_facet Verma, Shailendra Kumar
Mahajan, Pooja
Singh, Nikhlesh K.
Gupta, Ankit
Aggarwal, Rupesh
Rappuoli, Rino
Johri, Atul Kumar
author_sort Verma, Shailendra Kumar
collection PubMed
description In the present scenario, immunization is of utmost importance as it keeps us safe and protects us from infectious agents. Despite the great success in the field of vaccinology, there is a need to not only develop safe and ideal vaccines to fight deadly infections but also improve the quality of existing vaccines in terms of partial or inconsistent protection. Generally, subunit vaccines are known to be safe in nature, but they are mostly found to be incapable of generating the optimum immune response. Hence, there is a great possibility of improving the potential of a vaccine in formulation with novel adjuvants, which can effectively impart superior immunity. The vaccine(s) in formulation with novel adjuvants may also be helpful in fighting pathogens of high antigenic diversity. However, due to the limitations of safety and toxicity, very few human-compatible adjuvants have been approved. In this review, we mainly focus on the need for new and improved vaccines; the definition of and the need for adjuvants; the characteristics and mechanisms of human-compatible adjuvants; the current status of vaccine adjuvants, mucosal vaccine adjuvants, and adjuvants in clinical development; and future directions.
format Online
Article
Text
id pubmed-9998920
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99989202023-03-11 New-age vaccine adjuvants, their development, and future perspective Verma, Shailendra Kumar Mahajan, Pooja Singh, Nikhlesh K. Gupta, Ankit Aggarwal, Rupesh Rappuoli, Rino Johri, Atul Kumar Front Immunol Immunology In the present scenario, immunization is of utmost importance as it keeps us safe and protects us from infectious agents. Despite the great success in the field of vaccinology, there is a need to not only develop safe and ideal vaccines to fight deadly infections but also improve the quality of existing vaccines in terms of partial or inconsistent protection. Generally, subunit vaccines are known to be safe in nature, but they are mostly found to be incapable of generating the optimum immune response. Hence, there is a great possibility of improving the potential of a vaccine in formulation with novel adjuvants, which can effectively impart superior immunity. The vaccine(s) in formulation with novel adjuvants may also be helpful in fighting pathogens of high antigenic diversity. However, due to the limitations of safety and toxicity, very few human-compatible adjuvants have been approved. In this review, we mainly focus on the need for new and improved vaccines; the definition of and the need for adjuvants; the characteristics and mechanisms of human-compatible adjuvants; the current status of vaccine adjuvants, mucosal vaccine adjuvants, and adjuvants in clinical development; and future directions. Frontiers Media S.A. 2023-02-24 /pmc/articles/PMC9998920/ /pubmed/36911719 http://dx.doi.org/10.3389/fimmu.2023.1043109 Text en Copyright © 2023 Verma, Mahajan, Singh, Gupta, Aggarwal, Rappuoli and Johri https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Verma, Shailendra Kumar
Mahajan, Pooja
Singh, Nikhlesh K.
Gupta, Ankit
Aggarwal, Rupesh
Rappuoli, Rino
Johri, Atul Kumar
New-age vaccine adjuvants, their development, and future perspective
title New-age vaccine adjuvants, their development, and future perspective
title_full New-age vaccine adjuvants, their development, and future perspective
title_fullStr New-age vaccine adjuvants, their development, and future perspective
title_full_unstemmed New-age vaccine adjuvants, their development, and future perspective
title_short New-age vaccine adjuvants, their development, and future perspective
title_sort new-age vaccine adjuvants, their development, and future perspective
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998920/
https://www.ncbi.nlm.nih.gov/pubmed/36911719
http://dx.doi.org/10.3389/fimmu.2023.1043109
work_keys_str_mv AT vermashailendrakumar newagevaccineadjuvantstheirdevelopmentandfutureperspective
AT mahajanpooja newagevaccineadjuvantstheirdevelopmentandfutureperspective
AT singhnikhleshk newagevaccineadjuvantstheirdevelopmentandfutureperspective
AT guptaankit newagevaccineadjuvantstheirdevelopmentandfutureperspective
AT aggarwalrupesh newagevaccineadjuvantstheirdevelopmentandfutureperspective
AT rappuolirino newagevaccineadjuvantstheirdevelopmentandfutureperspective
AT johriatulkumar newagevaccineadjuvantstheirdevelopmentandfutureperspective